Good catch. Hopefully CLARIFIED and DISCUSSIONS included one Dr. Robert Daum. -IF- so -AND- no SAEs, we are golden.
"Naturally, the stock will clearly rise further on FDA APPROVAL." Obviously, stocks ALWAYS rise further on FDA APPROVAL, there's not a single case where a stock dropped on FDA APPROVAL.
What volatility? A week ago the trading pattern suggested NO SELLERS. In other words, the DVAX shorts were already in trouble. For any attempt to buy a significant number of shares would have undoubtedly resulted in a sharp increase in the share price.
Triple thumbs up in our board leader chiming in. I hang on and adore your every word Warren, er I mean jdoob.
In my paper trader mind I have a large position, but in reality but a *gnat-like position.
•a person or thing seen as tiny or insignificant, especially in comparison with something larger or more important.
Responding if I may for Isaac, "That does not compute Will Robinson."
The truth? WE CAN'T HANDLE THE TRUTH!
May many thumbs down befall you dvaxbeowulf !
1. A state of violent mental agitation or wild excitement.
2. Temporary madness or delirium.
3. A mania; a craze.
IMAGINE there's no trial hold
It's easy if you try
No SAE below us
Above us only share that sky
Imagine all the shareholders
Living for today
You may say Isaac's a dreamer
But he's not the only one
I hope someday you'll join us
And the longs will be as one
Good research. Oops though, that good research could get you multiple "thumbs down" as the conclusion was counter to "DVAX to the moon."
Update is supposed to occur in Feb. And what's the chance an FDA-appointed panel of vaccine experts leaks? Just asking.
Not much to elaborate. Assume we're where we are, 18. Then bases on my little off-the-cuff guess, that'd mean up to $25 inter-day and in follow-on days a sustained price $20.50ish.
Indeed. Positive seems very likely at this juncture, and should propel the stock substantially IMO. I figure more-or-less on a MAX inter-day upswing of 5-7.50, with a sustained gain of 2.50ish.
I did some looking and encountered several PDFs from GSK on Cervarix.
BLA was based on:
HPV-008, an efficacy study that enrolled 18665 (1:1)
HPV-013, a 3-4 year safety study that enrolled 2067 (1:1)
Counting up enrollment of all studies, I got enrollment: 33594
Considering the basis of the successful BLA was a population of (18665 + 2067 ) / 2 = 10366 that received Cerverix, then my conclusion based on the BLA is that Heplisav is in-line with "approvable on safety" based on the post HB-23 pooled total enrollment around 13,000. Great (hopefully)!
Excellent discussion, thx for your inquisitiveness and input.